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Abstract
Studies investigating factors affecting prognosis in primary myelofibrosis have been numerous over
the years because of the high heterogeneity with regard to its natural clinical course. Recently, the
increasing application of reduced-intensity conditioning with allogeneic hematopoietic stem cell
transplantation as well as the ongoing rapid development of new experimental agents, such as JAK2
inhibitors, have made the requirement for simple and accurate scoring systems to select individual
patients for the most appropriate treatment strategy even more critical. This short report
summarizes the state of the art and the most recent advances in this area.
Introduction and context
Primary myelofibrosis (PMF), also known as agnogenic
myeloid metaplasia or chronic idiopathic myelofibrosis,
is definitely the most heterogeneous among the Phila-
delphia chromosome (Ph)-negative chronic myeloproli-
ferative diseases with regard to clinical characteristics and
natural disease history. As a consequence, life expecta-
tion of patients diagnosed with this malignancy can vary
from very few to several years, depending on a variety of
disease and patient characteristics. Even though new
agents (in particular the JAK2 tyrosine-kinase inhibitors)
currently under investigation appear promising, to date
allogeneic hematopoietic stem cell transplantation (allo-
HSCT) remains the only potentially curative treatment
approach for patients with PMF. Because this disease
occurs mainly in middle aged and elderly patients, with
a median age at presentation of 67 years [1], transplant
strategies are mainly based on reduced intensity con-
ditioning (RIC) regimens [2,3]. Indeed, in the recent
years RIC allo-HSCT has increasingly been investigated
[4-8] with encouraging results. Therefore, identification
of prognostic factors in PMF is crucial in order to select
patients who might benefit from allogeneic transplanta-
tion, as well as patients who could be enrolled in trials
investigating new agents with partially unknown toxicity.
Patient and disease characteristics associated with shorter
survival by multivariate analyses performed in large
retrospective series of patients with PMF in the past
15 years [9-12] are summarized in Table 1. Among all
factors independently associated with a poorer prog-
nosis, anemia has constantly appeared to be one of the
most important and has thus invariably been included in
all the scoring systems proposed to stratify patients
according to the risk of death from the disease [9-13]. In
particular, the proportion of PMF patients reported as
having a hemoglobin level of <10 g/dL at diagnosis
ranged from 35-44%, depending on the series, while
patients presenting with a hemoglobin level of <8 gm/dL
were reported to represent 20% of all PMF patients [13].
The causes of anemia in PMF are various, with reduction
in medullary erythropoiesis, ineffective extramedullary
erythropoiesis and splenic destruction of circulating red
blood cells being the most important.
As in other hematological malignancies, advanced age is
also associated with a worse prognosis in PMF [9].
However, because in some studies the identification
of adverse features has been especially aimed at allo-
wing selection of patients who could be eligible for
allo-HSCT - that is, they have included in the analyses
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significantly associated with shorter survival [10-12].
With regard to the total leukocyte count at presentation,
both leukocytopenia (with white blood cell counts lower
than 4 × 10
9/L) and leukocytosis (with white blood cell
counts higher than 30 × 10
9/L) have consistently been
reported as independently associated with inferior
survival [10-12] in PMF.
Circulating blasts or circulating immature granulocytes
have been associated with shorter survival in most
studies [9,10,13], whereas the absolute content of
CD34+ cells in the peripheral blood, which has been
associated with both shorter survival and a smaller
interval to blast transformation in one study [14],
correlated with the presence of blood blasts but not
with survival in other patient populations when adjusted
by other covariates [15,16].
Thrombocytopenia (platelet counts <100 × 10
9/L),
which is seen in 25% of patients at diagnosis [15] and
becomes more common with disease progression, was
incorporated among the adverse prognostic factors in the
complete blood count (CBC)-based scoring systems
recently published by the Mayo Clinic [11,12].
Constitutionalsymptoms,includingseverefatigue,weight
loss, low-grade fever, and night sweats are quite common
in PMF, especially when patients develop massive
hepatosplenomegaly, and represent a well-established
risk-factor finding according to most authors [9-11].
With regard to cytogenetics, in PMF the high frequency of
‘dry tap’ during bone marrow aspirate makes it difficult
to obtain assessable metaphases for the analysis of
karyotypes. Nonetheless, the negative prognostic impact
of cytogenetic abnormalities in PMF has been indicated
by several studies [17-20]. Also, even if generally not
included in the scoring systems, cytogenetic abnormal-
ities emerged as independent factors in all the retro-
spective multivariate analyses performed on the largest
series of patients [9-11].
Recent advances
At the end of 2008, the International Working Group for
Myelofibrosis Research and Treatment (IWG-MRT)
published the results of a prominent multicenter retro-
spective study that included 1,054 patients consecutively
diagnosed with PMF, representing the largest patient
population ever analyzed [15], with the aim of identify-
ing adverse prognostic factors. The series included
patients of all ages from the databases of seven
important reference institutions and led to the proposal
of a new simple prognostic model based on five risk
factors (Tables 2 and 3).
Table 1. Factors associated with shorter survival by multivariate analysis in four published studies on PMF patients and the ensuing scoring
systems
Risk factor Dupriez et al.[ 9 ]
(195 pts)
Cervantes et al. [10]
(121 pts*)
Dingli et al. [11]
(160 pts
†)
Elliott et al. [12]
(129 pts
†)
Hemoglobin (g/dL) <10
‡ <10
‡ <10
‡ <10
‡
Age (years) >60
WBC (×10
9/L) <4, >30
‡ <4, >30
‡ <4, >30
‡
Platelets (×10
9/L) <100
‡ <100
‡
Peripheral blasts (%) >2 ≥1
‡
Monocytes (×10
9/L) >1.0
‡
Constitutional symptoms Present Present
‡ Present
Hepatomegaly Present
Sex Male
Karyotype Abnormal Unfavorable Unfavorable
≤ ≤
Interm, intermediate; PMF, primary myelofibrosis; pts, patients; WBC, white blood cell.
Table 2. Factors associated with shorter survival by multivariate
analysis in the study by the IWG-MRT [15]
Risk factor Hazard ratio (95% CI)
Age >65 years 1.95 (1.61-2.36)
Constitutional symptoms 1.97 (1.62-2.40)
Hemoglobin <10 g/dL 2.89 (2.46-3.61)
WBC count >25 × 10
9/L 2.40 (1.83-3.14)
Peripheral blasts ≥1% 1.80 (1.50-2.17)
CI, confidence interval; WBC, white blood cell. This research was originally
published in Blood. Cervantes et al. A new prognostic scoring system for
primary myelofibrosis based on a study of the International Working Group
for Myelofibrosis Research and Treatment. Blood 2008, 113:2895-901.
© American Society of Hematology.
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months) High (13) High (23.5) High (26)
(median survival in Interm (26) High (33) Interm (69) Interm (61)
Prognostic risk groups Low (93) Low (176) Low (155) Low (173)
*Patients included in this study were aged 55 years. Patients included in this study were aged 60 years. Factors included in the ensuing scoring system. † ‡Unlike in almost all previous similar reports, in this
study leukocytosis (with 25 × 10
9/L as the best cut-off
level for the white blood cell count) but not leukocyto-
penia was shown to retain prognostic significance by
multivariate analysis [15]. Interestingly, a strong associa-
tion between thrombocytopenia and anemia was
unveiled, so that thrombocytopenia did not have
prognostic significance in anemic patients, while anemia
retained its prognostic value in both patients with and
without thrombocytopenia [15].
Besides leukocytosis and anemia, the IWG-MRT analysis
pointed towards an age >65 years, presence of constitu-
tional symptoms, and circulating blasts ≥1% as other
independent risk factors associated with shorter survival
in PMF (Table 2) [15].
The prognostic role of absolute monocytosis (that is,
monocytes count greater than 1 × 10
9/L) in PMF is
controversial. In fact, although in 2007 a renovated
analysis performed by the Mayo Clinic [12] in a very
well-selected PMF patient population demonstrated that
the inclusion of monocytosis among factors previously
incorporated in their simple CBC-based ‘Mayo’ prog-
nostic scoring system [11] (that is, hemoglobin level,
leukocyte count and platelet count) led to a better risk
stratification of patients with PMF in comparison to
other accepted scoring systems [9-11], the poor prog-
nostic influence of a high monocyte count was not
confirmed in the most recent analysis of the IWG-MRT.
Nonetheless, it should be emphasized that in this latter
study differential counts were available in only 64% of
cases [15].
Regarding cytogenetics, it is worth mentioning that an
association of abnormal karyotypes with shorter survival
was also observed in the IWG-MRT study, although by
the multivariate Cox model this factor emerged as
contributing to prognosis only in the two intermediate-
risk groups [15].
Although variable, some degree of marrow fibrosis is
seen in almost all patients with myelofibrosis, and is
therefore considered the hallmark of this disease.
Grading of myelofibrosis in trephine bone marrow
biopsies, however, is mainly based on subjective evalua-
tion by individual pathologists. Therefore, in 2005 a
European consensus recommended the use of four easily
reproducible categories (MF-0, MF-1, MF-2, MF-3) for
bone marrow fibrosis [21]. A recent study addressed the
question of whether bone marrow fibrosis grading may
play a prognostic role in PMF by analyzing 98 patients
diagnosed with the disease strictly in accordance with the
last World Health Organization criteria [22], actually
showing that survival was significantly shorter in the
patients with MF-3 than in those with lower stages of
fibrosis [23].
The frequency of the JAK2 V617F mutation ranges from
43-63% in PMF, but its prognostic impact is currently
unclear.Indeed,themutationwasassociatedwithshorter
survival in one retrospective study of 152 patients [24],
whereas a subsequent prospective study including 174
patients demonstrated a correlation between the V617F
mutation and evolution towards large splenomegaly,
need for splenectomy, and leukemic transformation, but
not survival [25]. Similarly, no association of the JAK2
mutation with survival was observed in a series of 117
patients from the Mayo Clinic [26]. In the most recent
study by the IWG-MRT, no association with survival was
observed, but it should be remarked that information on
the JAK2 V617F mutation status was available for only
33% of the patients included in the study [15].
Although rare, transformation to acute leukemia is a
possible event in PMF. However, most prognostic studies
in this disease have focused on risk factors for overall
survival. In 2008, clinical variables at the time of
diagnosis and specific treatment modalities were ana-
lyzed for their effect on leukemic transformation in
311 patients with primary myelofibrosis [27]. By multi-
variate analysis, circulating blasts ≥3% and platelet
count <100 × 10
9/L were found to be independent
predictors of leukemic transformation. The evaluation of
treatment effect on leukemic transformation surprisingly
revealed an independent association with previous
erythropoiesis-stimulating agents or danazol, even when
the aforementioned prognostic indicators at the time of
diagnosis were added as covariates to the multivariate
model, obviously demanding further validation by
prospective studies.
Implications for clinical practice
The identification of prognostic factors in PMF that might
be used to design scoring systems able to stratify patients
Table 3. New scoring system for PMF proposed by the IWG-MRT
[15]
Risk group No. of factors Median survival (95% CI)
Low 0 135 months (117-181)
Intermediate-1 1 95 months (79-114)
Intermediate-2 2 48 months (43-59)
High ≥3 27 months (23-31)
CI, confidence interval; IWG-MRT, International Working Group for Myelo-
fibrosis Research and Treatment; PMF, primary myelofibrosis. This research
was originally published in Blood. Cervantes et al. A new prognostic scoring
system for primary myelofibrosis based on a study of the International
Working Group for Myelofibrosis Research and Treatment. Blood 2008,
113:2895-901. © American Society of Hematology.
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is critical and has considerable practical implications.
Indeed, scoring systems could allow selection of patients
who might be candidates for allo-HSCT, conventional or
experimentaldrugtherapy,orstrategiesbasedonwatchful
waiting, depending on the individual level of risk.
In comparison to previous ones [9-13], the new scoring
system proposed by the IWG-MRT has higher discrimi-
nating power, showing high reproducibility and pre-
dictive accuracy [15]. In particular, this system was
shown to discriminate four risk groups with no overlap
of their survival curves (Table 3). Because this model was
identified through a retrospective analysis of a very large
PMF population including patients of all ages, it should
also be particularly helpful in stratifying risk categories
according to life expectations among elderly patients,
who, in highly selected cases, might still benefit from a
RIC allo-HSCT treatment-based strategy. At the same
time, the new IWG-MRT scoring system could be applied
to discriminate between patients with very low risk who
should only be observed over time, and those whose
level of risk might justify their enrolment in trials with
new experimental drugs.
Nonetheless, even though the risks of morbidity and
mortality associated with allo-HSCT have decreased with
the introduction of RIC regimens, they still remain
significant, so when selecting patients for this treatment
it is crucial to not only bear in mind the risk of death
from the disease but also to take into account the risk of
death from the transplant procedure [28]. In any case,
allo-HSCT should still be considered an experimental
treatment in PMF, and should be performed only in the
context of controlled clinical trials.
To conclude, it is important to stress that all the PMF
prognostic scores so far developed, including the new
IWG-MRT scoring system, apply only to patients at
diagnosis. However, because we do not have other
criteria, in clinical practice we also utilize these scores
after initial treatments, or at the time of disease
progression. Indeed, as for other hematological malig-
nancies, allogeneic transplants performed in low-risk
versusintermediate/high-riskPMFpatientshavedifferent
outcomes. It should be noted, however, that no study has
proventhatthepreviouslymost widelyapplied classifica-
tion system (the Lille score) [9] and the following ones,
including the new IWG-MRT score [10-12,15], have the
same utility when used at times other than diagnosis.
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